Antipsychotic use in pregnancy

Area of Science:

• Perinatal Psychiatry
• Pharmacology
• Maternal-Fetal Medicine

Background:

• Increasing prescription of antipsychotic medications for women with mental illnesses.
• Limited evidence on the safety of antipsychotic use during pregnancy.
• Growing concerns among pregnant women and clinicians regarding medication safety.

Purpose of the Study:

• To review existing data on the safety of antipsychotic medications in pregnancy.
• To focus on the safety profiles of commonly prescribed atypical antipsychotics.
• To inform clinical practice and address concerns of pregnant patients.

Main Methods:

• Systematic review of published literature.
• Analysis of data on antipsychotic drug safety in pregnancy.
• Focus on commonly used atypical antipsychotics: olanzapine, risperidone, and quetiapine.

Main Results:

• No consistent evidence of congenital harm or specific malformations (limb, organ) associated with olanzapine, risperidone, and quetiapine.
• Potential association between antipsychotic use in pregnancy and gestational diabetes.
• Observed association between antipsychotic medication use and increased neonatal respiratory distress and withdrawal symptoms.

Conclusions:

• Careful administration of antipsychotics is recommended for pregnant women with severe mental disorders.
• Balancing maternal mental health with fetal and infant well-being requires further research.
• Ongoing studies are crucial for refining clinical guidelines on antipsychotic use in pregnancy.